Recently, Ringene Biopharma, an innovative drug R&D company focusing on the development of drugs targeting RTK-RAS-MAPK signaling pathway, independently developed a new class of anti-tumor drugs, the irreversible pan-FGFR inhibitor RG002, which was approved clinical. The indications are advanced malignant tumors.
In the R&D of RG002, Shanghai Medicilon Inc. provides drug discovery sevices in the form of FTE collaboration to clinical application, including preclinical research, drug discovery, pharmaceutical research and preclinical research (pharmacy, safety assessment), which accelerated the research process of RG002.
In the early stages of new drug development, FTE (Full-time equivalent) is often used by drug discovery companies to synthesize the required structural fragments and/or potential candidate compounds to accelerate the drug screening process.
Medicilon provides comprehensive chemistry research services covering all stages of your project requirements, and customers can cooperate with us through the FFS (Fee for Service) or FTE (Full-time Equivalent Service) models. Medicilon FTE/FFS service scope covers medicinal chemistry, synthetic chemistry, analytical chemistry.
Medicilon's one-stop preclinical biopharmaceutical R&D service platform covers the whole process of preclinical new drug research, including drug discovery, pharmaceutical research and preclinical research. A one-stop R&D platform, strong integration of advantageous resources, promotion of efficient cross-departmental collaboration and full use of the synergistic effect of 1+1>2, could accelerate the development of new drugs. With one-stop seamless R&D services, highly flexible new drug R&D plans, and effective time and cost control, Medicilon's one-stop preclinical biopharmaceutical R&D service platform has helped many new drugs be approved for clinical use.
Medicilon FTE services & FFS services - flexible and efficient cooperation model
ABM Therapeutics presented Medicilon with a commemorative trophy of "our first candidate compound"
Medicilon assists Ringene Biopharma 's SHP2 allosteric inhibitor RG001 tablet to be approved for clinical use
Share：
Relevant
news
marketing@medicilon.com
